Ascorbate Plus Buformin in AML: A Metabolic Targeted Treatment

Ascorbate Plus Buformin in AML: A Metabolic Targeted Treatment

In the present study, we characterized the metabolic background of different Acute Myeloid Leukemias’ (AMLs) cells and described a heterogeneous and highly flexible energetic metabolism. Using the Seahorse XF Agilent, we compared the metabolism of normal hematopoietic progenitors with that of primar...

Full description

Bibliographic Details
Main Authors: Cristina Banella, Gianfranco Catalano, Serena Travaglini, Elvira Pelosi, Tiziana Ottone, Alessandra Zaza, Gisella Guerrera, Daniela Francesca Angelini, Pasquale Niscola, Mariadomenica Divona, Luca Battistini, Maria Screnci, Emanuele Ammatuna, Ugo Testa, Clara Nervi, Maria Teresa Voso, Nelida Ines Noguera
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Cancers
Subjects:
Acute Myeloid Leukemia
Seahorse XF
metabolism
pharmacologic activity
ascorbate
buformin
Online Access:https://www.mdpi.com/2072-6694/14/10/2565

Internet

https://www.mdpi.com/2072-6694/14/10/2565

Similar Items